Oncolytics Biotech (TSE:ONC) Share Price Crosses Above 200-Day Moving Average of $1.68

Oncolytics Biotech Inc. (TSE:ONC) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$1.68 and traded as high as C$1.74. Oncolytics Biotech shares last traded at C$1.69, with a volume of 142,533 shares changing hands.

Wall Street Analyst Weigh In

ONC has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Oncolytics Biotech in a research report on Friday, January 12th. Raymond James set a C$3.00 target price on shares of Oncolytics Biotech and gave the stock an “outperform” rating in a report on Thursday, April 4th.

Oncolytics Biotech Price Performance

The company has a debt-to-equity ratio of 1.54, a quick ratio of 8.86 and a current ratio of 9.01. The company has a market cap of C$127.46 million, a P/E ratio of -4.12 and a beta of 1.49. The firm’s fifty day moving average is C$1.47 and its two-hundred day moving average is C$1.68.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings data on Thursday, March 7th. The company reported C($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.15) by C$0.10. As a group, analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.